The latest generation of beta-blockers: New pharmacologic properties

Current Hypertension Reports

Volumn 8, Issue 4, 2006, Pages 279-286

  Pedersen, Michala E ^b   Cockcroft, John R ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALPHA 1 ADRENERGIC RECEPTOR; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; FOSINOPRIL; INDAPAMIDE; LABETALOL; METOPROLOL; N(G) METHYLARGININE; NEBIVOLOL; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PERINDOPRIL; PLACEBO; PROPRANOLOL; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ANGINA PECTORIS; AORTA PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RECEPTOR BINDING; ENDOTHELIAL DYSFUNCTION; FOREARM BLOOD FLOW; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; MORBIDITY; MORTALITY; REVIEW; RIGIDITY; UNSPECIFIED SIDE EFFECT; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CORONARY CIRCULATION; ENDOTHELIUM, VASCULAR; FOREARM; HUMANS; REGIONAL BLOOD FLOW; STROKE VOLUME; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 33747605611     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-006-0065-0     Document Type: Review

References (78)

1. Egan BM, Basile J, Chilton RJ, Cohen JD: Cardioprotection: the role of beta-blocker therapy. J Clin Hypertens (Greenwich) 2005, 7:409-416.
2. Hollenberg NK: The role of beta-blockers as a cornerstone of cardiovascular therapy. Am J Hypertens 2005, 18(Suppl 1):165S-168S.
3. Bristow MR: Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000, 101:558-569.
4. Hebert PR, Moser M, Mayer J, et al.: Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993, 153:578-581.
5. Cockcroft JR, Dollery CT: The diuretic dilemma. In The Handbook of Hypertension, vol. 13: The Management of Hypertension. Edited by Bühler FR, Laragh JH. Amsterdam: Elsevier; 1990:202-216.
6. MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992, 304:405-412.
7. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
8. Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000, 356:1955-1964.
9. Staessen JA, Wang J-G, Thijs L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001, 358:1305-1315.
10. Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003, 362:1527-1535.
11. Lindholm LH, Carlberg B, Samuelsson O: Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005, 366:1545-1553.
12. Carlberg B, Samuelsson O, Lindholm LH: Atenolol in hypertension: Is it a wise choice? Lancet 2004, 364:1684-1689.
13. Dahlöf B, Devereux RB, Kjeldsen SE, et al.: for the LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
14. Dahlöf B, Sever PS, Poulter NR, et al.: for the ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
15. Beevers DG: The end of beta-blockers for uncomplicated hypertension? Lancet 2005, 366:1510-1512.
16. O'Rourke MF, Brunner HR: Introduction to arterial compliance and function. J Hypertens Suppl 1992, 10:S3-S5.
17. O'Rourke MF, Kelly RP: Wave reflection in the systemic circulation and its implications in ventricular function. J Hypertens 1993, 11:327-337.
18. Nichols WW: Clinical measurement of arterial stiffness obtained from non-invasive pressure waveforms. Am J Hypertens 2005, 18(Suppl 1):S3-S1O.
19. Wilkinson IB, Cockcroft JR: Cholesterol, endothelial function and cardiovascular disease. Curr Opin Lipidol 1998, 9:237-242.
20. Polonia J, Barbosa L, Silva JA, Maldonado J: Different influences on central and peripheral pulse pressure, aortic wave reflections and pulse wave velocity of three different types of antihypertensive drugs. Rev Port Cardiol 2003, 22:1485-1492.
21. Morgan T, Lauri J, Bertram D, Anderson A: Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004, 17:118-123.
22. Hirata K, Vlachopoulos C, Adji A, O'Rourke MF: Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery? J Hypertens 2005, 23:551-556.
23. Chen C-H, Ting C-T, Lin S-J, et al.: Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension 1995, 25:1034-1041.
24. Dhakam Z, McEniery CM, Yasmin, et al.: Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006, 19:214-219.
25. Asmar RG, London GM, O'Rourke ME, Safar ME, for the REASON Project coordinators and investigators: Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/ indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001, 38:922-926.
26. Resnick LM, Lester MH: Differential effects of antihypertensive drug therapy on arterial compliance. Am J Hypertens 2002, 15:1096-1100.
27. Cockcroft JR, Brown MJ: Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study. Lancet 2002, 359:2202-2204.
28. The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 113:1213-1225.
29. Wilkinson IB, McEniery CM, Cockcroft JR: Atenolol and cardiovascular risk: an issue close to the heart. Lancet 2006, 367:627-629.
30. Kelly R, Daley J, Avolio A, O'Rourke M: Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension. Hypertension 1989, 14:14-21.
31. Schächinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000, 101:1899-1906.
32. Al Suwaidi J, Hamasaki S, Higano ST, et al.: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101:948-954.
33. Chowienczyk PJ, Watts GF, Cockcroft JR, Ritter JM: Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet 1992, 20:490-491.
34. Calver A, Collier J, Vallance P: Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992, 90:2548-2554.
35. Celermajer DS, Sorensen KE, Georgakopoulos D, et al.: Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993, 88:2149-2155.
36. Wilkinson IB, Prasad K, Hall IR, Thomas A: Increased central pulse pressure and augmentation index in subjects with hypercholesterolemia. J Am Coll Cardiol 2002, 39:1005-1011.
37. Wilkinson IB, MacCallum H, Rooijmans DF, et al.: Increased augmentation index and systolic stress in type 1 diabetes mellitus. Q J Med 2000, 93:441-448.
38. Ceravolo R, Maio R, Pujia A, et al.: Pulse pressure and endothelial dysfunction in never-treated hypertensive patients. J Am Coll Cardiol 2003, 41:1753-1758.
39. Wilkinson IB, Qasem A, McEniery CM, et al.: Nitric oxide regulates local arterial distensibility in vivo. Circulation 2002, 105:213-217.
40. Schmitt M, Avolio A, Qasem A, et al.: Basal NO locally modulates human iliac artery function in vivo. Hypertension 2005, 46:227-231.
41. Wilkinson IB, Franklin SS, Cockcroft JR: Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology. Hypertension 2004, 44:112-116.
42. Levy D, Larson MG, Vasan RS, et al.: The progression from hypertension to congestive heart failure. JAMA 1996, 275:1557-1562.
43. Chae CU, Pfeffer MA, Glynn RJ, et al.: Increased pulse pressure and risk of heart failure in the elderly. JAMA 1999, 281:634-639.
44. Domanski MJ, Mitchell GF, Norman JE, et al.: Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. J Am Coll Cardiol 1999, 33:951-958.
45. Sutton-Tyrrell K, Najjar SS, Boudreau RM, et al.: for the Health ABC Study: Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 2005, 111:3384-3390.
46. Roman MJ, Ganan A, Saba PS, et al.: Impact of arterial stiffening on left ventricular structure. Hypertension 2000, 36:489-494.
47. Mitchell GF, Tardif J-C, Arnold JM, et al.: Pulsatile hemodynamics in congestive heart failure. Hypertension 2001, 38:1433-1439.
48. Mottram PM, Haluska BA, Leano R, et al.: Relation of arterial stiffness to diastolic dysfunction in hypertensive heart disease. Heart 2005, 91:1551-1556.
49. Kawaguchi M, Hay I, Fetics B, Kass DA: Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003, 107:714-720.
50. Ramsey MW, Goodfellow J, Jones CJ, et al.: Endothelial control of arterial distensibility is impaired in chronic heart failure. Circulation 1995, 92:3212-3219.
51. Nakamura M, Sugawara S, Arakawa N, et al.: Reduced vascular compliance is associated with impaired endothelium-dependent dilatation in the brachial artery of patients with congestive heart failure. J Card Fail 2004, 10:36-42.
52. Cheung YF, Chan GCF, Ha SY: Arterial stiffness and endothelial function in patients with β-thalassemia major. Circulation 2002, 106:2561-2566.
53. MacCarthy PA, Shah AM: Impaired endotheliumdependent regulation of ventricular relaxation in pressure-overload cardiac hypertrophy. Circulation 2000, 101:1854-1860.
54. Fischer D, Rossa S, Landmesser U, et al.: Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 2005, 26:65-69.
55. Paulus WJ, Bronzwaer JGF: Nitric oxide's role in the heart: control of beating or breathing? Am J Physiol Heart Circ Physiol 2004, 287:H8-H13.
56. Janssens S, Pokreisz P, Schoonjans L, et al.: Cardiomyocytespecific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 2004, 94:1256-1262.
57. Cotton JM, Kearney MT, MacCarthy PA, et al.: Effects of nitric oxide synthase inhibition on basal function and the force-frequency relationship in the normal and failing human heart in vivo. Circulation 2001, 104:2318-2323.
58. Loke KE, McConnell PI, Tuzman JM, et al.: Endogenous endothelial nitric oxide synthase-derived nitric oxide is a physiological regulator of myocardial oxygen consumption. Circ Res 1999, 84:840-845.
59. Giugliano D, Marfella R, Acampora R, et al.: Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care 1998, 21:631-636.
60. Ma X-L, Gao F, Nelson AH, et al.: Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats. J Pharmacol Exp Ther 2001, 298:879-885.
61. Lopez BL, Christopher TA, Yue TL, et al.: Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. Pharmacology 1995, 51:165-173.
62. Yoshioka T, Iwamoto N, Tsukahara F, et al.: Anti-NO action of carvedilol in cell-free system and in vascular endothelial cells. Br J Pharmacol 2000, 129:1530-1535.
63. Bowman AJ, Chen CP L-H, Ford GA: Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994, 38:199-204.
64. Cockcroft JR, Chowienczyk PJ, Brett SE, et al.: Nebivolol vasodilates human forearm vasculature: evidence for L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995, 274:1067-1071.
65. Dawes M, Brett SE, Chowienczyk PJ, et al.: The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol 1999, 48:460-463.
66. Tzemos N, Lim PO, MacDonald TM: Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001, 104:511-514.
67. Ritter JM: Nebivolol: endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol 2001, 38(Suppl):S13-S16.
68. Pauwels PJ, Gommeren W, Van Lommen G, et al.; The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various betaadrenergic blockers. Mol Pharmacol 1988, 34:843-851.
69. Prichard BN, Cruickshank JM, Graham BR: Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press 2001, 10:366-386.
70. Bakris GL, Fonseca V, Katholi RE, et al.: for the GEMINI Investigators: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004, 292:2227-2236.
71. Poirier L, Cléroux J, Nadeau A, Lacourcière Y: Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 2001, 19:1429-1435.
72. McEniery CM, Schmitt M, Qasem A, et al.: Nebivolol increases arterial distensibility in vivo. Hypertension 2004, 44:305-310.
73. Packer M, Bristow MR, Cohn JN, et al.; for the U.S. Carvedilol Heart Failure Study Group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 334:1349-1355.
74. Packer M, Coats AJ, Fowler MB, et al.; for the Carvedilol Prospective Randomized Cumulative Survival Study Group: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
75. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
76. CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13.
77. Kitzman DW, Gardin JM, Gottdiener JS, Boineau AA; for the CHS: Importance of heart failure with preserved systolic function in patients >65 years of age. Am J Cardiol 2001, 87:413-419.
78. Flather MD, Shibata MC, Coats AJS, et al.; on behalf of the SENIORS Investigators: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005, 26:215-225.